Account
Inquiry
Retatrutide (LY3437943) is a potent GLP-1 receptor agonist developed for research in weight management and metabolic studies. Clinical trials have demonstrated its efficacy, with phase 2 results showing over 24% mean weight reduction in non-diabetic obese or overweight adults. It is important for researchers to note that while Retatrutide shares mechanisms with semaglutide, its side effect profile may differ; however, common semaglutide side effects such as gastrointestinal discomfort should be considered during experimental design.
This product is supplied as a white powder with high stability under recommended storage conditions. It is intended solely for research applications and must not be used for human consumption. Proper handling and adherence to storage guidelines are crucial to maintain integrity and performance in experimental settings.
Researchers should be aware of potential semaglutide side effects when working with GLP-1 agonists, including nausea or hypoglycemia, though Retatrutide's unique formulation may alter these risks. Always follow institutional safety protocols.
Available in multiple vial sizes for flexibility in dosing and study design. Each batch is rigorously tested to ensure consistency and reliability for scientific investigations.
For long-term storage, keep at -20°C to preserve efficacy. Short-term storage at 0-4°C is acceptable, but avoid repeated freeze-thaw cycles. Solubility and specific drug formulation details should be determined based on experimental requirements.
This product is ideal for academic, pharmaceutical, and clinical research focused on obesity, diabetes, and metabolic disorders. Understanding semaglutide side effects can help in designing comparative studies with Retatrutide.
